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Abstract: Despite the availability of anti-retroviral therapy, HIV-1 infection remains a massive
burden on healthcare systems. Bacillus Calmette-Guérin (BCG), the only licensed vaccine against
tuberculosis, confers protection against meningitis and miliary tuberculosis in infants. Recombinant
BCG has been used as a vaccine vehicle to express both HIV-1 and Simian Immunodeficiemcy
Virus (SIV) immunogens. In this study, we constructed an integrative E. coli-mycobacterial shuttle
plasmid, p2auxo.HTI.int, expressing the HIVACAT T-cell immunogen (HTI). The plasmid was
transformed into a lysine auxotrophic Mycobacterium bovis BCG strain (BCG∆Lys) to generate the
vaccine BCG.HTI2auxo.int. The DNA sequence coding for the HTI immunogen and HTI protein
expression were confirmed, and working vaccine stocks were genetically and phenotypically
characterized. We demonstrated that the vaccine was stable in vitro for 35 bacterial generations, and
that when delivered in combination with chimpanzee adenovirus (ChAd)Ox1.HTI in adult BALB/c
mice, it was well tolerated and induced HIV-1-specific T-cell responses. Specifically, priming with
BCG.HTI2auxo.int doubled the magnitude of the T-cell response in comparison with ChAdOx1.HTI
alone while maintaining its breadth. The use of integrative expression vectors and novel HIV-1
immunogens can aid in improving mycobacterial vaccine stability as well as specific immunogenicity.
This vaccine candidate may be a useful tool in the development of an effective vaccine platform for
priming protective responses against HIV-1/TB and other prevalent pediatric pathogens.
Keywords: BCG; HIV; vaccine; rBCG; HTI; T-cell
1. Introduction
According to the latest reports, there are currently 37 million people infected with HIV, the majority
of whom live in sub-Saharan Africa [1]. Despite the existence of anti-retroviral therapy, 1.8 million
people were newly infected in 2017, and almost one million people died due to HIV-related disease [1].
Developing a safe, efficacious, and accessible HIV vaccine would be the optimal solution for the
prevention of HIV-1 infection as well as reduction of HIV-related diseases. Evidence demonstrating
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the role of T-cell responses directed against HIV-1 in the control of viral replication is growing [2,3].
HIV-1-specific CD8+ T-cells have been detected in exposed seronegative individuals, and CD8+
cytotoxic T-lymphocytes (CTL) responses targeting HIV-1 Gag have been associated with reduced viral
loads in infected individuals [4–6].
The “HIVACAT T-cell immunogen” (HTI) was designed to cover T-cell targets, against which
T-cell responses are predominantly observed in HIV-1-infected individuals with low HIV-1 viral
loads [7]. This immunogen has been manufactured as naked DNA, as well as introduced into viral
vaccine vectors and an immunization regimen consisting of three injections of DNA encoding HTI
followed by a boost with modified vaccinia Ankara (MVA)-vectored HTI has been shown in C57BL/6
mice to result in the induction of HIV-1 specific T-cell responses to most antigen regions included
in its design. High magnitudes of HIV-1 specific T-cells were also induced in macaques following
three injections of DNA.HTI and two injections of MVA.HTI [7]. It is well known that delivering a
boosting injection of an immunogen using a viral vector such as MVA can boost the response of DNA
immunization and increase the magnitude of responses. Such heterologous prime-boost regimens
have been used for a number of immunogens in the context of HIV [8].
Upon intramuscular delivery, DNA vaccines are thought to induce cellular immunity through
antigen synthesis and presentation to T-cells. The immunity is induced by the direct transfection
of antigen-presenting cells (APCs) or through cross-presentation by APCs [9,10]. Similar to DNA,
the Mycobacterium bovis strain, Bacillus Calmette-Guérin (BCG), when used as a vaccine vector also
induces immunity by targeting APCs, although this occurs not through transfection, but rather through
infection. Recombinant BCG is a promising live attenuated bacterial vaccine vector for inducing T-cell
immunity, as it is a slow-growing organism that provides a persistent low-level antigenic exposure upon
the infection of macrophages and APCs, and could drive effector and memory T-cell responses [11].
In the context of anti-tuberculosis (anti-TB) immunity, the pathogen for which BCG currently is licensed
as a vaccine, immune responses in humans are predominantly T helper 1 (Th1)-cell mediated. Infected
dendritic cells migrate to lymph nodes and activate antigen-specific CD4+ T-cells in the presence of
cytokines such as interleukin (IL)-18 and IL-12 [12]. The T-cell repertoire induced by vaccination is
broad, targeting multiple mycobacterial antigens [13]. BCG is safe and is currently administered to
80% of infants in countries where it is part of the national childhood immunization program [14].
Aside from the induction of anti-TB immune responses, vaccination has been linked to decreased
mortality due to other infections in infants [15,16]. This phenomenon has been related to the enhanced
monocyte function observed in humans following vaccination, which is characterized by CD11b, TLR-4
expression, and increased cytokine production [17].
Recombinant BCG (rBCG) has been utilized as a vector to express HIV-1/Simian Immunodeficiency
Virus (SIV) antigens and assessed regarding the induction of specific T-cell responses in several animal
models [18]. The need for adjuvants is overcome as its cell-wall peptidoglycans and lipoproteins
act as an adjuvant on their own [19–22]. BCG also has several advantages as a live vaccine vehicle,
it is easy to mass-produce with low cost, and is heat stable [23]. It is also suitable for neonates,
as vaccination is not affected by maternal antibodies [24,25]. Finally, it has a proven safety record
after having been delivered as a TB vaccine to over three billion individuals [26]. As with DNA
vaccination, rBCG-based HIV vaccines on their own may induce low-level specific immune responses,
and thus they are often combined with virally vectored immunogens in heterologous prime-boost
vaccination regimens where they have been shown to increase HIV-1 specific immune responses [27–30].
However, a rBCG expressing HIV-1 group M consensus Env vaccine on its own was shown to induce
comparable immune responses both in the female reproductive tract and lungs when compared
with adenovirus prime/recombinant vaccinia virus boost immunization [31]. The applicability of
rBCG as a priming agent was demonstrated by Ami et al., where priming with rBCG and boosting
with a replication-deficient vaccinia virus strain expressing SIVgag was able to confer protection
in Cynomolgus macaques against mucosal challenge with pathogenic SHIV. Interestingly, effective
protection was not achieved in animals receiving the opposite combination or the vaccine modalities
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delivered on their own [32]. These data support the use of rBCG as a priming vector for an HIV-1
vaccine, whereby the use of rBCG could potentially strengthen or qualitatively modify the immune
response when combined with DNA and/or a viral vector expressing an HIV-1 immunogen.
Here, we present the construction and characterization of recombinant BCG expressing the
HTI immunogen, the BCG.HTI2auxo.int vaccine, harboring the integrated 2auxo expression cassette
in their chromosome. The HTI immunogen has previously been assessed in mice and macaques
when delivered as a prime-boost regimen vectored by DNA and MVA [7]. We demonstrate that
BCG.HTI2auxo.int delivered in combination with ChAdOx1.HTI increases the HIV-1 specific T-cell
responses in adult BALB/c mice. Priming with wild type BCG (BCGwt) was also shown to similarly
increase the magnitude of the response, but significantly decreased the breadth of the T-cell responses.
Furthermore, we demonstrate that priming with rBCG, in some mice, can alter the immunodominance
profile of the vaccine-induced T-cell response.
2. Materials and Methods
2.1. Construction of the BCG.HTI2auxo.int Strain Using an Antibiotic-Free Plasmid Selection System
The double auxotrophic E. coli–mycobacterial shuttle integrative vector, the p2auxo.int plasmid,
was previously constructed in our laboratory [33]. This vector contains the glyA and LysA genes,
which function as an antibiotic-free selection and maintenance system in the auxotrophic strains of
E. coli M15∆glyA and BCG∆Lys, respectively. It also contains sites (attP) for integration into the BCG
genome at the attB site. The synthetic sequence of HTI [7] was codon-optimized for BCG expression to
match the G+C rich mycobacterial codon usage for enhanced expression [34]. The HTI G+C rich DNA
sequence was synthesized by Geneart (USA) and ligated to the integrative p2auxo.int plasmid fused to
the 19-kDa lipoprotein secretion signal sequence generating p2auxo.HTIint. The ligation products were
subsequently transformed into the E. coli M15∆glyA strain for growth and selection.
2.2. Bacterial Cultures and Transformation
Cells of the glycine auxotrophic strain of E. coli, M15∆Gly, provided by Dr. Pau Ferrer (Universitat
Autònoma de Barcelona, Spain), were cultured in LB supplemented with glycine (70 µg/mL). The E. coli
M15∆Gly cells were transformed with the p2auxo.HTIint plasmid by electroporation. For this, the E. coli
cultures were grown to an optical density of 0.125 at 600 nm, as well as concentrated and transformed
using a Bio-Rad gene pulser electroporator at 2.5 kV, 25 µF, and 200 Ω. The transformed cells were
subsequently cultured on M9-D agar plates (minimal M9-derivative medium: Na2HPO4, 6.78 g/L;
KH2PO4, 3 g/L; NaCl, 0.5 g/L; NH4Cl, 1 g/L, glucose, 10 g/L; MgSO4, 2 mmol/L; CaCl2, 0.1 mmol/L;
thiamine, 0.1 g/L; FeCl3, 0.025 g/L; AlCl3·6H2O, 0.13 mg/L; ZnSO4·7H2O, 2.6 mg/L; CoCl2·6H2O, 0.47
mg/L; CuSO4·H2O, 4.6 mg/L; H3BO3, 0.03 mg/L; MnCl2·4H2O, 4.2 mg/L; NiCl2·6H2O, 0.02 mg/L;
Na2MoO4·2H2O, 0.06 mg/L, with 1.5% bactoagar added) without glycine supplementation for selection
or with glycine supplementation as a control. The QIAprep Spin Miniprep Kit was used according
to the manufacturer’s instructions (Qiagen, Hilden, Germany) to extract plasmid DNA from E. coli.
The resulting plasmids were tested for identity and correct insertion by PCR and restriction enzyme
profiling. The selected plasmid was transformed into BCG∆lys.
The lysine auxotrophic BCG strain, BCG∆lys, kindly provided by W.R. Jacobs Jr., B.R. Bloom, and
T. Hsu (Albert Einstein College of Medicine, New York, NY, USA), was transformed with p2auxo.HTIint
plasmid by electroporation. The mycobacteria were cultured in Middlebrook 7H9 broth medium
or on Middlebrook agar 7H10 medium supplemented with albumin–dextrose–catalase (ADC; Difco
Laboratories, Franklin Lakes, NJ, USA) containing 0.05% Tween 80. L-lysine monohydrochloride
(Sigma) was dissolved in distilled water and used as a supplement at a final concentration of 40
µg/mL. For transformation, BCG was cultured to an optical density of 1.5 at 600 nm, washed with
10% glycerol, concentrated, and transformed using a Bio-Rad gene pulser electroporator at 2.5 kV, 25
µF, and 1000 Ω. Then, the transformants were cultured on ADC-supplemented Middlebrook agar
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7H10 medium containing 0.05% Tween 80 without lysine supplementation. The resulting colonies
were assessed for plasmid insertion, integrity, and HTI expression. From a selected colony, a Master
Seed (MS) and a Working Vaccine Stock (WVS) were produced according to the seed lot system. For
the BCG substrain identification assay, the commercial BCG Danish 1331 strain (Pfizer, New York,
NY, USA) kindly provided by Dr. Neus Altet (Urology Department at Hospital Clínic de Barcelona,
Barcelona, Spain), and the commercial BCG Connaught strain (ImmuCyst, Aventis, Paris, France) were
used as standards.
2.3. Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis and Western Blot Analysis
Cell lysates of mid-logarithmic phase BCG transformants were prepared by sonication in a protein
extraction buffer (50 mmol/L Tris–HCl pH 7.5, 5 mmol/L Ethylenediaminetetraacetic acid (EDTA),
0.6% sodium dodecyl sulfate) containing protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO,
USA). Cell lysates supernatants were subsequently separated by a Novex 4–12% Bis-Tris SDS-PAGE
gel (Thermo Fisher Scientific, Waltham, MA, USA), and electroblotted onto a pretreated polyvinylidene
difluoride membrane using an iBlot kit (Thermo Fisher Scientific, Waltham, MA, USA). The HTI protein
was stained using the primary anti-HTI monoclonal antibodies n63 and n69 at 5 µg/mL overnight kindly
provided by Aelix Therapeutics (Barcelona) followed by secondary goat anti-mouse Immunoglobulin
G-Horse Radish Peroxidase(IgG–HRP) antibody (Jackson ImmunoResearch, Cambridgeshire, UK) for
1 h diluted at 1:10,000. The membrane was developed using the SuperSignal™ West Femto Maximum
Sensitivity Substrate kit (Thermo Fisher Scientific, Waltham, MA, USA).
2.4. In Vitro Stability of the BCG.HTIint Strain
Five subcultures (∼35 bacterial generations) from the MS of BCG.HTI2auxo.int harboring the
p2auxo.HTIint plasmid DNA (two selected clones) containing the lysine complementing gene were
cultured in 7H9 Middlebrook broth with and without L-lysine selection. Subcultures were performed
every 7 days by transferring 100µL of the stationary phase culture to 5 mL of fresh medium. PCR analysis
of the HTI DNA coding sequence were performed using insert specific primers designed at both HTI 3’
and 5’ sequences. PCR product size from the p2auxo.HTI.int plasmid and subcultures were compared.
2.5. Mycobacterial Genomic DNA Preparation for the Multiplex PCR Assay and for attR and attL DNA
Regions PCR
For isolation of DNA from BCGwt, BCG.HTI2auxo.int; 2 mL of mycobacterial culture was centrifuged
at 5000 rpm for 10 min at room temperature. The pellet was resuspended in 200 µL of distilled water
and heated at 95 ◦C for 20 min to inactivate and lyse bacterial cells. The sample was next centrifuged
at a speed of 13,000× g. A total of 5 µL of supernatant was used for the amplification reaction.
The commercial BCG strains were treated similarly, except in this case, 400 µL of the reconstituted
freeze-dried flasks were used.
2.6. Multiplex PCR Assay for M. bovis BCG Substrain Pasteur Identification
The multiplex PCR assay was performed as described previously by Bedwell et al. [35], using 5 µL
of mycobacterial DNA isolated from BCG.HTI2auxo.int, BCG wt (Pasteur strain, kindly provided by
W.R. Jacobs Jr., B.R. Bloom, and T. Hsu (Albert Einstein College of Medicine, New York, NY, USA)),
and commercial BCG strains as template in a final reaction volume of 50 µL.
2.7. Immunization of Mice and Isolation of Splenocytes
Groups of eight adult (seven-week-old) female BALB/c mice were immunized intradermally in
one footpad, and two groups were left unimmunized. The first group received 105 colony-forming
units (CFU) of BCG.HTI2auxo.int (Group A), the second group received 106 CFU of BCG wt (Group B),
both groups in one footpad. Two groups were left unimmunized (Groups C and D). ChAdOx1.HTI
Vaccines 2019, 7, 78 5 of 19
was constructed as previously described [36], and groups A–C were boosted intramuscularly with
109 viral particles (vp) after five weeks, while group D was left unimmunized. All the mice were
sacrificed two weeks after the boost for immunogenicity analyses. Immediately following sacrifice of
the animals, splenocytes were harvested and homogenized using 70 µm cell strainers (Falcon; Becton
Dickinson, Franklin Lakes, NJ, United States) and 5-ml syringe rubber plungers. Red blood cells were
removed with ACK lysing buffer (Lonza, Barcelona, Spain), and the splenocytes were washed and
resuspended in complete medium (R10 (RPMI 1640 supplemented with 10% fetal calf serum and
penicillin–streptomycin), 20 mmol/L of HEPES, and 15 mmol/L of 2-mercaptoethanol).
2.8. IFN-γ ELISpot Analysis
The Enzyme-linked immune absorbent spot (ELISpot) assay was performed using the commercial
murine IFN-γ ELISpot kit (Mabtech, Nacka Strand, Sweden) according to the manufacturer’s
instructions. The ELISpot plates (MSISP4510, 96-well plates with polyvinylidene difluoride membranes,
Millipore, USA) were 70% EtOH treated and coated with purified anti-mouse interferon-γ (IFN-γ)
capture monoclonal antibody diluted in phosphate-buffered saline (PBS) to a final concentration of
5 µg/mL at 4 ◦C overnight. Then, 250,000 fresh splenocytes were added to each well and stimulated
with 17 peptide pools containing a total of 147 15 mer overlapping peptides (OLP) spanning the HTI
sequence, at a concentration of 10 µg/mL per peptide. Tuberculin purified protein derivative (PPD,
AJ vaccines, Copenhagen, Denmark,) at a concentration of 5 µg/mL was used to assess TB-specific
responses. All the samples and controls were plated in duplicate wells. ELISpot assays were incubated
for 16 h at 37 ◦C, 5% CO2. The plates were subsequently washed 5×with PBS, incubated for 2 h with
a biotinylated anti-IFN-γ monoclonal antibody (mAb) diluted in PBS 2% Fetal Calf Serum (FCS) to
a final concentration of 2 µg/mL, washed 5× in PBS, and incubated with the streptavidin–alkaline
phosphatase conjugate in PBS 2% FCS. Then, plates were washed 5× with PBS before incubating with
100 µL of 5-bromo-4-chloro-3-indolyl phosphate (BCIP)/nitro blue tetrazolium (NBT) substrate solution
(Sigma-Aldrich, St Louis, MO, USA). After 5–10 min, the plates were washed with tap water, dried, and
the resulting spots counted using an ELISPOT reader (Autoimmune Diagnostika GmbH, Strassberg,
Germany). For each animal, the mean of background responses was subtracted individually from all
the wells to enable a comparison of the IFN-γ spot forming cells (SFC)/106 between groups. To define
positive responses, a threshold was defined as at least five spots per well, and responses exceeding
the mean number of spots in negative control wells plus three standard deviations of the negative
control wells.
2.9. Statistical Analysis
Immunogenicity data is represented as group means of the total IFN-γ SFC/106 response or as
medians for individual antigens/pools. Statistical differences were assessed by ordinary one-way
analysis of variance when comparing total ELISpot responses or the Kruskal–Wallis test when
comparing responses to individual pools. (* p < 0.05; ** p < 0.01; *** p < 0.001). GraphPad Prism 6.0
(Graphpad, San Diego, CA, USA) software was used. Body mass data are shown as group means with
error bars indicating standard deviation as well as means ± 2 standard deviation (SD) from naïve mice.
Statistical analyses were performed using the Kruskal–Wallis test.
2.10. Ethics Statement
The animal experiments strictly conformed to the animal welfare legislation of the Generalitat de
Catalunya. All the experiments were approved by the local Research Ethics Committee (Procedure
Med 365/16, Clinical Medicine, School of Medicine, University of Barcelona).
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3. Results
3.1. Construction of the BCG.HTI2auxo.int Vaccine Strain
In the p2auxo.HTIint E. coli-mycobacterial shuttle vector, the heterologous open reading protein
expression cassette is under the control of the Mtb α-antigen promoter, which is a weak promoter
that has been shown to enhance protein stability [37]. The open reading frame of the heterologous
protein is initiated by the mycobacterial 19-kDa protein signal sequence, which at its 5’ end was fused
to the HTI coding sequence. This enables the localization of the newly synthesized HTI polyprotein to
the mycobacterial membrane, and subsequently its secretion, to prevent the internal accumulation
of the heterologous protein and enhance protein immunogenicity (Figure 1A). The plasmid contains
the E. coli origin of replication (oriE), attachment sites (attP), and the integrase (int) genes from
the mycobacteriophage L5 [38], and integrates as a single copy into the attB region on the BCG
chromosome. The plasmid also contains the wild-type glycine A-complementing gene (glyA) and
lysine A-complementing gene (lysA5) for vector selection and maintenance in the auxotrophic E. coli
and BCG strain, respectively [39,40]. The p2auxo.HTIint was obtained following the methodology
previously described [33] and transformed into the glycine auxotrophic E. coli M15∆glyA strain and
the lysine auxotrophic BCG Pasteur strain (∆lysA5) [41,42]. The positive recombinant E. coli colonies
were selected through culture on Minimal M9-D agar plates and the BCG.HTI2auxo.int colonies on
Middlebrook agar 7H10 medium without lysine supplementation. Integration of the p2auxo.HTIint
plasmid DNA into the mycobacterial genome was assessed by PCR analysis of the attR and attL
DNA insertion regions. The BCG.HTI2auxo.int was used as a template, and bands of 766 bp and
874 bp corresponding to the attR and attL DNA regions were detected (Figure 1B), demonstrating that
p2auxo.HTIint had integrated at the attB genomic BCG DNA region. Expression of the full-size chimeric
19-kDa signal sequence-HTI protein was confirmed by Western blot analysis of BCG.HTI2auxo.int lysates
(Figure 1C). The selected clones were preserved using the seed-lot system. Clone #3 was selected as the
candidate, and Master Seed stocks and Working Vaccine Stocks were prepared for further molecular
characterization, immunogenicity, and safety testing in mice.Vaccines 2019, 7, x 7 of 20 
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Figure 1. Construction f the r combina t cillus Calm tte-Guérin HIVACAT T-cell immunogen
(BCG.HTI2auxo.int) strain. (A) The HTI synthetic sequence was BCG codon-optimized and fused to the
19-kDa lipoprotein signal sequence and inserted into the integrative p2auxo.HTIint E. coli-mycobacterial
shuttle plasmid. This vector contains P α-Ag, which is a Mycobacterium tuberculosis α-antigen promoter,
PHSP60, which is a heat shock protein 60 gene promoter. The glyA and LysA complementing genes
function as an antibiotic-free selection and maintenance system in the auxotrophic strains of E. coli
M15∆glyA and BCG∆Lys, respectively; (B) PCR analysis of recombinant BCG clones transformed with
p2auxo.HTIint for integration sites: “attR” (left panel; lanes 1–5; clones 1–5; lane 6: BCG.empty2auxo.int;
lane 7: molecular weight marker; lane 8: p2auxo.HTIint) and “attL” (right panel; lanes 1–5; clones 1–5;
lane 6: molecular weight marker; lane 7: p2auxo.HTIint; lane 8: BCG.empty2auxo.int), (C) PCR analysis
using primers specific for glyA (left) and HTI (right) on BCG transformed with p2auxo.HTIint lanes
1–5; clones 1–5; lane 6: BCG.empty2auxo.int; lane 7: molecular weight marker; lane 8: p2auxo.HTIint.
(D) Western blot of BCG.HTI2auxo.int lysates; lanes 1 and 7: Molecular weight marker; lanes 2 and 8:
Master Seed of BCG.HTI2auxo.int clone 1; lanes 3 and 9: Master seed of BCG.HTI2auxoint clone 3; lanes 4
and 10: Working Vaccine Stock of BCG.HTI2auxo.int clone 3; lanes 5 and 11: BCGwt (negative control);
lanes 6 and 12: purified recombinant HTI protein. The HTI proteins were detected using the n63 (left)
and n69 (right) mAbs directed against the HTI protein (AELIX Therapeutics, Barcelona, Spain) followed
by horseradish peroxidase-goat-anti-mouse and enhanced chemiluminescence (ECL) detection.
3.2. Genetic Identification and Characterization of BCG.HTI2auxo.int
To confirm that the identity of the BCG.HTI2auxo.int vaccine strains corresponded to the BCG
Pasteur substrain, a multiplex PCR-based method was performed to analyze the BCG regions of
difference such as RD1, 2, 8, 14, and 16 and the SenX3-RegX3 regions [35]. Different multiplex profiles
obtained by this method allow the differentiation of BCG substrains. A PCR product of 196-bp length
was generated using the primers ET1-3, indicating deletions of the RD1 region that were only found
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in BCG strains, not in the Mycobacterium bovis or Mycobacterium tuberculosis strains. The presence of
the RD8 and RD16 regions was confirmed in the BCG.HTI2auxo.int and the BCG Pasteur substrain,
which generated products of 472 bp and 401 bp, respectively. Products of 276 bp representing the
SenX3-RegX3 region were also found. The molecular patterns of the BCG Danish, BCG Connaught,
and BCG Pasteur substrains (Figure 2A) were consistent with previously published patterns [35].Vaccines 2019, 7, x 9 of 20 
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the HTI gene in the BCG.HTI2auxo.int WVS; lane 1: H2O; lane 2: p2auxo.HTIint plasmid; lane 3: working
vaccine stock of BCG.HTI2auxo.int; lane 4: BCG wt; lane 5: BCG transformed with empty 2auxo.int
plasmid; lane 6: molecular weight marker. (D) PCR detection of the GlyA gene in the BCG.HTI2auxo.int
working vaccine stock; lane 1: p2auxo.HTIint plasmid; lane 2: WVS of BCG.HTI2auxo.int; lane 3: BCGwt;
lane 4: BCG transformed with empty 2auxo.int plasmid; lane 5: water; lane 6: molecular weight marker.
PCR for right integration site, attR (E,F) left integration site, attL in the BCG.HTI2auxo.int WVS; lane 1
WVS of BCG.HTI2auxo.int; lane 2: BCGwt; lane 3: distilled water; lane 4: molecular weight marker; lane
5: positive control, BCG.HIVconsv12auxo.int Working Vaccine Stock (recombinant BCG expressing the
HIVconsv1 immunogen [36,43]).
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PCR and enzymatic restriction analysis were performed to characterize the p2auxo.HTIint plasmid
DNA. Following transformation of the E. coli M15 ∆glyA strain, plasmid DNA was purified, and
the enzymatic restriction analysis revealed results that were consistent with the predicted enzymatic
pattern (Figure 2B): ApaI digestion (Lane 2; bands of 4005 bp, 1907 bp, 974 bp, 787 bp, and 498 bp),
BamHI digestion (Lane 3; bands of 6280 bp and 2195 bp), Bsal digestion (lane 4; bands of 4648 bp,
1563 bp, and 686 bp), Stul digestion (Lane 5; bands of 4672 bp and 1931 bp). The empty plasmid
p2auxo.∅INT restriction enzyme pattern was also consistent with the expected band pattern: BamHI
(lane 6; 4672 bp and 2195 bp) and Notl (lane 7; bands of 3904 bp and 2963 bp). Next, we performed
PCR analysis using specific primers for the HTI and E. coli glyA DNA coding sequences using the
BCG.HTI2auxo.int Working Vaccine Stock as template. Bands of 1581 bp and 1760 bp corresponding to
the expected size of HTI (Figure 2C) and the E. coli glyA DNA sequence (Figure 2D) were detected.
Furthermore, PCR analysis using specific primers designed for 3’ and 5’ HTI ends was employed to
confirm integration of the p2auxo.HTIint plasmid DNA into the parental BCG∆lysA strain genome.
The BCG.HTI2auxo.int Working Vaccine Stock was used as a template. Bands of 766 bp and 874 bp
corresponding to the respective attR (Figure 2E) and attL (Figure 2F) attachment sites were detected in
Working Vaccine Stocks, but not in BCG wt. The HTI DNA coding sequence was detected by PCR in
the BCG.HTI2auxo.int after 35 bacterial generations (Appendix A Figure A1).
3.3. Phenotypic Characterization of BCG.HTI2auxo.int
To preserve plasmid stability, both in vivo and in vitro, as well as to prevent potential genetic
rearrangements, several factors should be considered when constructing mycobacterium-based vaccine
candidates. We previously demonstrated that the use of weak promoters (Mycobacteria spp. α-antigen
promoter) and use of the BCG lysine auxotrophy-complementation system prevent the disruption
of gene expression due to genetic rearrangements [33,37]. The lysine auxotrophic BCG strain was
used in combination with lysine gene complementation as an antibiotic-free plasmid selection and
maintenance system. To phenotypically assess the stability and demonstrate the lack of antibiotic
resistance of this system, the BCG.HTI2auxo.int strain was cultured on non-lysine-supplemented agar
with and without kanamycin. In line with previous findings, the untransformed lysine auxotrophic
BCG strain failed to grow without the presence of lysine and grew upon supplementation with lysine
(Figure 3A,B). The BCG.HTI2auxo.int strain, on the other hand, grew on non-lysine supplementation
(Figure 3C), and did not grow on agar plates containing kanamycin (Figure 3D).
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Figure 3. Phenotypic characterization of the BCG.HTI2auxo.int vaccine strain. Phenotype of lysine
auxotrophy, lysine complementation, and kanamycin resistance. The BCG lysine auxotroph prior to
transformation with p2auxo.HTIint was cultured on non-lysine supplemented 7H10 (A) or on lysine
supplemented 7H10 (B). The BCG.HTI2auxo.int WVS was cultured on 7H10 without lysine or kanamycin
supplementation or without lysine but with kanamycin supplementation (C,D, respectively).
3.4. The BCG.HTI2auxo.int prime-ChAdOx1.HTI Boost Regimen Elicits HIV-1-Specific T-cell Responses
In order to assess the enhancement of cellular immune responses provided by a prime vaccination
with BCG.HTI2auxo.int, adult mice (seven-week-old, n = 8/group) we immunized w th either 105 cfu of
BCG.HTI2auxo.int (id) and boosted with ChAdOx1.HTI 109 viral particles (vp) delivered intramuscularly
(im) after five weeks (group A), or with 106 BCGwt (id) and boosted with ChAdOx1.HTI (109 vp,
im) after five weeks (group B), or only immunized with ChAdOx1.HTI (109 vp, im) at week five
(group C), or left unimmunized (group D). The groups and immunization regimens are illustrated
in Figure 4A. A group primed with BCGwt was included to allow comparison of the unspecific
adjuvanticity of BCG and the specific priming of BCG expressing HTI. Two weeks post-boost, mice
were sacrificed and splenocytes were isolated for an ELISpot analysis of IFN-γ secretion in response to
17 peptide pools spanning the HTI proteome. The total magnitude of IFN-γ secreting cells in response
to HTI peptide pools was approximately doubled when priming with BCG.HTI2auxo.int as compared to
ChAdOx1.HTI alone; however, the same was observed in BCGwt primed mice (Figure 4B). Overall,
priming with BCG.HTI2auxo.int or BCGwt increased responses to peptide pools in the responding
mice (Figure 4C–E), although these differences only reached trends when compared with animals
only receiving ChAdOx1.HTI. In mice immunized with ChAdOx1.HTI alone, statistically significant
differences as compared to naïve mice were only observed in response to one pool representing integrase
(int) (pool 2C, Figure 4D). Priming with BCG.HTI2auxo.int induced significantly higher responses as
compared to naïve mice in response to five HTI-derived pools (Figure 4: 1E p24; p = 0.0469, 1H p24;
p = 0.048, 1K prot; p = 0.0004, 2B RT; p = 0.0011, and 2C int; p = 0.0038). A similar number was observed
for mice primed with BCGwt (Figure 4: 1G p24; p = 0.0016, 1K prot; p = 0.0002, 2B RT; p = 0.0004,
and 2C int; p = 0.0360). However, the IFN-γ response to pool 1E representing p24 was significantly
higher in mice receiving BCG.HTI2auxo.int as compared to those receiving BCGwt (Figure 4C). Both the
recombinant and wild-type BCG induced Mtb-specific responses (PPD, Figure 4E).
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Figure 4. Induction of HIV-1 specific T-cell responses by the BCG.HTI2auxo.int + chimpanzee adenovirus
HIVACAT T-cell immunogen (ChAdOx1.HTI) prime-boost regimen in BALB/c mice. Adult mice (seven
weeks old, n = 8/group) were immunized with either 105 cfu of BCG.HTI2auxo.int (id) and boosted
with ChAdOx1.HTI (109 vp, im) after five weeks (group A), or with 106 BCG.wt (id) and boosted
with ChAdOx1.HTI (109 vp, im) after five weeks (group B), or only immunized with ChAdOx1.HTI
(109 vp, im) at week five (group C), or left unimmunized (group D). Groups and the immunization
schedule are shown in (A). Two weeks post-boost, mice were sacrificed, and splenocytes were isolated
for enzyme-linked immune absorbent spot (ELISpot) analysis. (B) The total magnitude of HIV-1 specific
SFCs/106 splenocytes was calculated as sums of the SFCs elicited by the 17 HTI peptide pools, the
color-coding represents the HIV-1 gene location of the pools. Data are presented as group means
and error bars represent the standard deviation of the total sum of SFC/106 splenocytes. Statistics
were performed using parametric one-way ANOVA. (C-E) HIV-1 and tuberculosis (TB)-specific T-cell
responses interferon-γ (IFN-γ spot-forming cells SFC/106 in response to HTI-derived peptide pools
representing HIV-1 Gag (C), HIV-1 Pol (D), and Nef, Vif, and tuberculin purified protein derivative
(PPD) (E). The data are presented as medians of group responses above the threshold. Statistics were
performed using the non-parametric Kruskal–Wallis test adjusted for multiple comparisons, *p < 0.05,
**p < 0.01, ***p <0.001 and ****p < 0.0001.
Interestingly, a comparison of the average number of reactive HTI peptide pools in vaccinated
mice revealed that the number of reactive pools in BCGwt primed mice was significantly lower than
in those primed with BCG.HTI2auxo.int (Figure 5A, p = 0.0262). This indicates a loss of breadth when
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priming with BCGwt, even though IFN-γ secreting cells in response to HTI peptide pools were similar
when compared with BCG.HTI2auxo.int primed mice. No differences between BCG.HTI2auxo.int primed
mice as compared to mice only receiving ChAdOx1.HTI (Figure 5A) were observed regarding the
number of pools recognized per mouse, although the mean was slightly increased from 7.3 to 7.8 when
priming with BCG.HTI2auxo.int. The highest number of recognized peptide pools was 13 in both groups.
Interestingly, certain mice of the BCG.HTI2auxo.int + ChAdOx1.HTI immunized group reacted to pools
less frequently recognized by other groups (Figure 5B: 1E p24, 1F p24, 1J prot, 2D int). On the other
hand, lower numbers of mice recognized certain peptide pools (Figure 5B: 1G p24, 1H p24, 2E Vif)
when compared to mice only immunized with ChAdOx1.HTI.Vaccines 2019, 7, x 13 of 20 
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BCG.HTI2auxo.int (id) and boosted ith ChAdOx1.HTI (109 vp, im) after fiv weeks (group A), or with
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group according to peptid pool and HIV-1 gene location. Statistics were performed using arametric
one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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3.5. The BCG.HTI2auxo.int + ChAdOx1.HTI Prime-Boost Regimen Is Well Tolerated
Five adult mice per group were either left unimmunized or received 106 colony-forming units (cfu)
of BCG wt or a total of 105 cfu of BCG.HTI2auxo.int intradermally, and five weeks later were boosted
with 109 vp of ChAdOx1.HTI and their body mass was monitored regularly over time (Figure 6).
The body mass curve corresponded to those of the provider (Envigo, Huntington, UK), and there were
no statistically significant differences observed between the vaccine recipients and controls at any time
point tested (Figure 6). Mice were monitored weekly for signs of malaise. No vaccine-related deaths,
no local adverse events, and no associated systemic reactions were observed.Vaccines 2019, 7, x 14 of 20 
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4. Discussion
Despite the exploration and implementation of numerous HIV-1 prevention strategies, 1.8 million
new HIV infections occurred in 2017 [44]. There is an urgent need for the developme t of an effective,
safe, and affordable HIV-1 vaccin . We have constructed rBCG vaccine candi ate ex ressing the
HIVACAT T-cell immunogen, HTI, using the integrative antibiotic-resist ce free E. coli-mycobacterial
shuttle vector, p2auxo.int. The HTI immunogen was designed to target T-cell responses to the most
beneficial T-c ll targets and the most v lnerable sites of HIV-1. Wh deliver d using DNA and MVA
vect rs, it has been shown to be capable of inducing broadly and evenly distributed immune r sponses
of high magnitude in mic and monkeys [7]. We have previously d monstrated the in vitro and in vivo
stability of the integrative plasmid p2auxo.int for expressing HIV-1 immunogens in BCG [33,43]. Here,
we produc t BCG.HTI2auxo.int accine candidates under Good Laboratory Practice compatible
conditions, and characterized them genotypically and phenotypically, confirming the pr ence of
the HTI gene and protein in the lysat s of worki g vaccine sto ks. Further ore, we demonstrate
t at the BCG.HTI2auxo.int vaccine in combination with ChAdOx1.HTI induced TB and HIV-1-specific
IFN-γ-producing T-cell r sponses in dult BALB/c mice. The vaccination regimen was well tolerated
during the follow- p period, although a longer safety assessment will be neces ary, as symptoms
related to a la k of attenuation of mycobacteria coul take at l ast 50 days to emerge and impact body
mass in the ouse model [45].
BCG is a remarkable live vaccine vehicle due to its capability of delivering antigens to APCs
enabling the development of antige -sp cific cell-mediated immune responses [24]. Mycobacterial
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antigens have been shown to be presented to T-cells by non-classical antigen presentation molecules
such as CD1a/b/c, Major histocompatibility complex class I-related gene protein (MR1), and Human
leukocyte antigen-E (HLA-E). The latter is of specific interest in the context of HIV-1 vaccine development
due to the resistance of HLA-E to downregulation by the HIV-1 Nef during infection [46], as well
as displaying a low level of allelic variation, with only forty three existing variants as opposed
to the thousands of classical HLA class I molecules [47]. Furthermore, BCG-immunized humans
elicited HLA-E restricted CD8+ T-cell responses to Mtb peptides, which display cytotoxic as well as
immunoregulatory activities [48]. One of the most successful HIV-related vaccine trials in animal
models has been a Cytomegalovirus (CMV) vectored vaccine against SIV. This vaccine was able to
establish persistent, SIV-specific effector memory T-cell responses in rhesus macaques and control
pathogenic SIV infection following mucosal challenge [49]. CMV infection is known to upregulate
HLA-E expression in humans, and the vaccine regimen in the monkeys induced strong Mamu-E
restricted T-cell responses [50]. It is still unknown if BCG can elicit a similar immune response to a
heterologous antigen when used as a vaccine vector in humans. However, BCG administered as an
oral adjuvant along with inactivated simian immunodeficiency virus (SIV)mac239 particles in Chinese
macaques was shown to confer protection to a high-dose SIVmac239 challenge [51]. The protection was
attributed to non-cytolytic Major histocompatibility complex (MHC) Ib/E-restricted CD8+ T-regulatory
cells that suppressed the activation of SIV-positive CD4+ T-lymphocytes.
As a vector, rBCG shares several traits with plasmid DNA. Both are often used as priming agents
in combination with a virally vectored boost [8,24]. A rBCG–DNA prime-boost regimen showed less
immunogenicity when explored using the HIVA immunogen, as compared to boosting with viral
vectors [28]. On the other hand, a combination regimen of rBCG and DNA expressing HIVA was shown
to confer protection in a pathogenic vaccinia–HIVA surrogate challenge model [39]. However, little is
known about the advantages for specific immunity to heterologous immunogens upon combining
rBCG, DNA, and viral vectors.
Recombinant BCG delivered on its own induces weak transgene-specific immune responses that
are difficult to measure. Thus, we have assessed the enhancement of HIV-1 specific cellular immune
responses by a prime vaccination with BCG.HTI2auxo.int when delivered with ChAdOx1.HTI in BALB/c
mice. The magnitude of the total T-cell response was significantly higher in BCG.HTI2auxo.int primed
mice as compared to mice receiving ChAdOx1.HTI alone. A similar magnitude was observed in BCGwt
primed mice (Figure 4). The IFN-γ secretion in response to the individual HTI peptide pools was
higher in all the assessed pools, although the differences did not reach statistical significance between
mice receiving BCG prime and those not. The evident priming effect, even by BCGwt, is in line with
the ability of BCG derivatives to act as potent adjuvants for subsequent boosting vaccines. It is known
that immunization with BCG not expressing any transgene often can lead to higher vaccine-specific
responses when delivered as a prime/adjuvant in combination with a virally vectored vaccine [39,52].
Components of BCG have also been used as an adjuvant for an HIV-1 DNA vaccine [53].
Interestingly, both BCG.HTI2auxo.int primed mice and mice receiving ChAdOx1.HTI alone
responded to an average of seven to eight peptide pools, whereas mice primed with BCGwt alone only
responded to an average of 4.5 peptide pools. This together suggests that priming with BCG.HTI2auxo.int
enhances the HTI-specific immune response when delivered with ChAdOx1.HTI, while maintaining
the breadth of the response. Priming with BCGwt appeared to boost the overall magnitude of the
response, but ultimately directing responses to fewer peptide pools. The differences in the breadth of
immune responses between the BCG.HTI2auxo.int and BCGwt could possibly be related to the strong
adjuvant properties of BCG. A possible explanation is its capability of inducing trained immunity.
This involves enhanced monocyte function and Natural killer (NK) cell function as reviewed by van
der Meer et al. [54]. Macrophages, monocytes, and natural killer cells display enhanced responsiveness
following a second encounter with a pathogen. Enhanced monocyte function has been demonstrated
in humans three months after BCG vaccination along with increased cytokine production, as well
as CD11b and toll-like receptor 4 (TLR-4) expression [17]. This effect could be observed up to one
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year following immunization [55]. The unspecific immune activation could perhaps be involved in
mechanisms enhancing the production of cytokines such as IFN-γ in T-cells, which leads to higher
responses in the epitopes, which are more dominant. It is notable that the HTI was designed to avoid
useless immunodominant epitopes in humans, but nevertheless, it is inevitable that there will be a
hierarchy of epitopes in mice in which cellular immune responses are elicited against. Thus, the higher
breadth observed following priming with the BCG.HTI2auxo.int could be related to the priming of
responses that are specifically related to the transgene expressed (HTI), whereas the general increase
in IFN-γ induced by BCGwt could be related to unspecific or adjuvanticity-related effects on the
immune system rather than the specific priming of immune responses directed toward HTI. Previously,
C57BL/6 mice immunized with DNA.HTI alone were shown to respond to two to six HTI peptide
pools, and following an immunization schedule consisting of three DNA.HTI prime immunizations
and one MVA.HTI immunization delivered at three-week intervals, this number was increased to six to
11 peptide pools [7]. Delivering a combination of BCG.HTI2auxo.int, DNA, and a viral vector expressing
HTI could present a strategy for increasing the number of recognized pools further.
Correlates of protection for HIV-1 vaccines have been discussed following the RV144 trial, such as
the IgG Ab response to the variable regions 1 and 2 (V1V2) loops being associated with a reduction
in HIV-1 acquisition [56]. However, the translatability of data obtained in small animal models is
limited, and pre-clinical design and the evaluation of HIV-1 vaccines remains a challenge. In humans,
T-cell responses have also been associated with protection or decreased viral loads following infection.
For instance, in the RV144 trial, CD4+ T-cells secreting IL-2, TNF-α, IFN-γ, IL-4, and CD154 in response
to HIV-1 envelope peptides were associated with lower infection rates in vaccine recipients [57].
5. Conclusions
We here demonstrate that priming with BCG.HTI2auxo.int significantly increased HTI-specific
T-cell responses. Although priming with BCGwt led to a similar enhancement of the magnitude of
the response, fewer peptide pools were recognized in BCGwt primed animals. The ability of the
BCG.HTI2auxo.int priming immunization to increase T-cell immune responses when combined with
ChAdOx1.HTI, while maintaining the breadth of the response, strengthens its applicability as a priming
vaccine for the development of an efficacious HIV-1 vaccine. Finally, we demonstrate that in some mice,
priming with BCG.HTI2auxo.int can alter the immunodominance profile of the vaccine-induced T-cell
response. Further assessments and characterization of the T-cell response by intracellular cytokine
staining would provide a more thorough overview of the vaccine-induced immune response and of
potential functional differences, depending on the different vaccination regimen.
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Figure A1. In vitro stability of BCG.HTI2auxoint. In vitro stability was assessed by PCR detection of
the HTI gene in the BCG.HTI2auxo.int master seeds after five weekly subcultures with and without
added lysine; lane 1; BCG.HTI2auxo.int clone 1; lane 2: BCG.HTI2auxo.int clone 3; lane 3: BCG.HTI2auxo.int
clone 1 cultured in lysine supplemented medium; lane 4: BCG.HTI2auxo.int clone 3 cultured in lysine
supplemented medium; lane 5: BCG.Ø2auxo.int; lane 6: distilled water; lane 7: p2auxo.HTI.int plasmid;
lane 8: molecular weight marker.
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